Acrobat Genomics

Acrobat Genomics is a biotechnology company that develops AI-driven protein and genome engineering solutions. Their technology platform integrates high-throughput functional screening within living human cells with machine learning to train AI models for the design and optimization of novel therapeutic molecules. By learning from millions of measurements taken directly in human cells, the company aims to move beyond traditional in silico discovery methods, enabling the rapid design of therapeutics that function effectively in complex biological environments.

The company serves the biotechnology and healthcare sectors by applying its platform to biosecurity and the development of gene editing-based therapeutics. As a prime contractor for programs such as the DARPA Rapid Inhibitor Discovery and Development pipeLine (RIDDL), Acrobat Genomics works to create rapid responses to emerging threats, including the development of novel inhibitors for gene editing technologies. Founded in 2022, the company has secured funding from the National Institutes of Health, private investors, and biopharma collaborators to advance its research in therapeutic applications and protein design.